Skip to content
type1.science

Abbott Libre Duo

Abbott

The world's first dual glucose-and-ketone sensor — one Libre 3-sized wearable that reads both glucose and ketones every minute. CE-marked in Europe (May 2026) with launch underway; US FDA approval is expected in the second half of 2026. A potential turning point for preventing diabetic ketoacidosis.

On the horizonRegulator-approvedcgmdual-analyteketone-sensing

The scorecard

Accuracy78

Glucose accuracy is expected on par with the Libre 3 platform it is built on; published per-sensor MARD for the Duo's glucose and ketone channels is not yet in the peer-reviewed literature, so scored conservatively.[1]

Low lag65

Interstitial glucose lag is inherent to the sensing method and not a differentiator; the value here is a second analyte, not lower lag.[1]

Interoperability70

Abbott is working with pump makers so AID systems can connect; Sequel's twiist has a public agreement to integrate the dual sensor once US-cleared. Ecosystem is committed but not yet shipping.[4]

Sensor lifespan85

Up to 15-day wear on the Libre Duo (adults); the Libre Duo 10 Day runs up to 10 days and covers ages 2+.[1]

No calibration90

Built on the factory-calibrated Libre 3 platform; no routine fingerstick calibration expected.[1]

Alerts & prediction85

Adds continuous ketone visibility on top of glucose alerts — flagging rising ketones that can precede diabetic ketoacidosis, a failure mode no glucose-only CGM can see.[1]

Form factor88

Same size as the FreeStyle Libre 3 sensor — among the smallest and thinnest on the market — now sensing two analytes in that footprint.[2]

Ketone sensing95

The headline feature: continuous interstitial beta-hydroxybutyrate measurement, the first of its kind — directly addresses today's biggest sensing gap.[1]

Access & cost30

Not yet broadly purchasable — CE-marked with a phased EU rollout starting late 2026; not cleared or sold in the US. Pricing not announced.[1]

The full picture

Abbott's Libre Duo is the first wearable that senses two things at once — your glucose and your ketones — from a single sensor the size of a FreeStyle Libre 3.12 Both values update every minute, so for the first time you can watch ketones the way you already watch glucose, without a fingerstick blood-ketone strip or a urine test that only captures a single moment.1

Why ketones matter. When insulin runs short — a kinked pump cannula, an illness, a missed dose, or while taking an SGLT2 inhibitor — ketones (specifically beta-hydroxybutyrate, or BHB) can climb toward diabetic ketoacidosis (DKA), a life-threatening emergency.34 Crucially, ketones can rise before glucose does, so a glucose-only CGM can look reassuring while trouble is already building.5 DKA is common, dangerous, and expensive — single episodes have been estimated to cost up to roughly $36,000.5 A diabetes expert consensus had specifically called for exactly this: one sensor that measures both glucose and BHB together.4 For context, BHB is usually under 0.5 mmol/L normally and can exceed 3 mmol/L in DKA.5

How it works and what you wear. The Libre Duo measures interstitial glucose and BHB using a single subcutaneous sensor.3 Two versions are CE-marked: the Libre Duo wears up to 15 days and is for adults 18+, while the Libre Duo 10 Day wears up to 10 days and covers ages 2 and older.16 It is built on the Libre 3 platform, which is factory-calibrated (no routine fingerstick calibration) and among the smallest CGMs available.2 It connects to Abbott's Libre app ecosystem, including caregiver sharing and cloud data for clinicians.2

Accuracy — what we can and can't say yet. Glucose accuracy is expected to track the well-established Libre 3 platform, but a published, peer-reviewed MARD for the Duo's glucose channel and a formal accuracy figure for its ketone channel are not yet available; early real-world data using the dual sensor are only now being reported.7 We will update this entry with hard numbers (including low-range performance) once the pivotal data are published. Treat the accuracy claims here as provisional.

Alerts and closed loops. Beyond standard glucose alerts, the headline is continuous ketone visibility, giving an early warning of rising BHB so you can act on sick-day rules before DKA.38 Abbott is working with pump makers so automated insulin delivery (AID) systems can use the sensor.1 Sequel Med Tech has a public agreement to integrate its twiist AID system (powered by Tidepool) with the dual sensor once it is US-cleared — pairing early ketone detection with twiist's insulin-delivery checks.9

Who it's for, access, and what's coming. It's aimed at anyone at risk of DKA — type 1 diabetes, insulin-treated type 2, SGLT2-inhibitor users, pregnancy, and children (via the 10 Day version).108 Today it is CE-marked in Europe (May 2026) with a phased EU launch starting later in 2026; it is not yet cleared or sold in the US, where Abbott — which holds FDA breakthrough device designation for the technology — expects approval in the second half of 2026.162 Pricing has not been announced.1 We flag this as a coming-soon device to watch closely.

References

  1. Abbott. Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes. Abbott Media Room (2026). https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. Abbott. Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System. Abbott Media Room (2022). https://abbott.mediaroom.com/2022-06-03-Abbott-Announces-Development-of-Novel-Continuous-Glucose-Ketone-Monitoring-System ↩ ↩2 ↩3 ↩4

  3. Miller E, Miller K, Bergenstal RM. Integrating Continuous Dual Glucose-Ketone Monitoring into Clinical Practice. Diabetes Technol Ther (2025). https://pubmed.ncbi.nlm.nih.gov/41267371/ ↩ ↩2 ↩3

  4. Virdi N, Poon Y, Abaniel R, Bergenstal RM. Prevalence, Cost, and Burden of Diabetic Ketoacidosis. Diabetes Technol Ther (2023). https://pubmed.ncbi.nlm.nih.gov/37306442/ ↩ ↩2

  5. Kerr D. Integrating Ketone and Glucose Monitoring for Optimized Diabetes Management: Highlights from the ADA 2025 Conference. Diabetes Metab Syndr Obes (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12319150/ ↩ ↩2 ↩3

  6. Reuter E. Abbott receives CE mark for dual glucose-ketone sensor. MedTech Dive (2026). https://www.medtechdive.com/news/abbott-receives-ce-mark-for-dual-glucose-ketone-sensor/821296/ ↩ ↩2

  7. Bergenstal RM, Virdi N, Quadri F, Alva S. Monitoring Ketonemia in People with Diabetes: Preliminary Findings from Real-World Studies. Diabetes Technol Ther (2025). https://pubmed.ncbi.nlm.nih.gov/41267372/ ↩

  8. Kong YW, Morrison D, Lu JC, et al. Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obes Metab (2024). https://pubmed.ncbi.nlm.nih.gov/39314201/ ↩ ↩2

  9. Sequel Med Tech. Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott's Future Dual Glucose-Ketone Sensor. GlobeNewswire (2025). https://www.globenewswire.com/news-release/2025/05/22/3086535/0/en/Sequel-Med-Tech-to-Integrate-twiist-Automated-Insulin-Delivery-AID-System-with-Abbott-s-Future-Dual-Glucose-Ketone-Sensor.html ↩

  10. Sherr JL, Cobry EC. The Future of Dual Glucose-Ketone Monitoring in Youth with Diabetes. Diabetes Technol Ther (2025). https://pubmed.ncbi.nlm.nih.gov/41267374/ ↩

Coming soon

ETA · CE-marked May 2026; EU rollout from late 2026; US FDA approval expected H2 2026

  • →EU market launch in select countries (phased), beginning late 2026
  • →US FDA approval expected in the second half of 2026 (breakthrough-designated)
  • →Integration with Sequel's twiist AID system once US-cleared, for closed-loop ketone awareness

Sources

  1. [1]Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes · manufacturer — Abbott press release, 27 May 2026 — CE mark, wear days, ages, every-minute sensing, EU/US status.
  2. [2]Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System · manufacturer — Abbott press release, 3 Jun 2022 — FDA breakthrough device designation; Libre 3-size form factor; one sensor for glucose + ketones.
  3. [3]Abbott receives CE mark for dual glucose-ketone sensor · news — MedTech Dive — independent confirmation of CE mark, wear/age specs, EU launch, US FDA expected H2 2026.
  4. [4]Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott's Future Dual Glucose-Ketone Sensor · manufacturer — Sequel/GlobeNewswire, 22 May 2025 — twiist AID + dual sensor integration agreement.
  5. [5]Prevalence, Cost, and Burden of Diabetic Ketoacidosis · peer-reviewed — Virdi et al., Diabetes Technol Ther 2023 (PMID 37306442, DOI 10.1089/dia.2023.0149) — DKA burden; expert consensus calling for a single dual glucose-BHB sensor.
  6. [6]Continuous ketone monitoring: Exciting implications for clinical practice · peer-reviewed — Kong et al., Diabetes Obes Metab 2024 (PMID 39314201, DOI 10.1111/dom.15921) — CKM feasibility, ~5-min updates, who benefits.
  7. [7]Monitoring Ketonemia in People with Diabetes: Preliminary Findings from Real-World Studies · peer-reviewed — Bergenstal et al., Diabetes Technol Ther 2025 (PMID 41267372, DOI 10.1177/15209156251390833) — early data from a study using the dual glucose-ketone sensor.
  8. [8]Integrating Continuous Dual Glucose-Ketone Monitoring into Clinical Practice · peer-reviewed — Miller et al., Diabetes Technol Ther 2025 (PMID 41267371, DOI 10.1177/15209156251392900) — describes the single-sensor interstitial glucose + BHB system.
  9. [9]The Future of Dual Glucose-Ketone Monitoring in Youth with Diabetes · peer-reviewed — Sherr & Cobry, Diabetes Technol Ther 2025 (PMID 41267374, DOI 10.1177/15209156251370944) — pediatric DKA case for continuous dual sensing.
  10. [10]Integrating Ketone and Glucose Monitoring: Highlights from the ADA 2025 Conference · peer-reviewed — Kerr, Diabetes Metab Syndr Obes 2025 (PMID 40761614, DOI 10.2147/DMSO.S555697) — BHB thresholds (<0.5 normal, >3 in DKA), sensor performance discussion.